XML 12 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Details Textual) (USD $)
 6 Months Ended 12 Months Ended 6 Months Ended 0 Months Ended 1 Months Ended 6 Months Ended 0 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2014
Dec. 31, 2013
Jun. 30, 2014
Medeor [Member]
Dec. 31, 2007
Licensing Agreements [Member]
Drugs
May 31, 2014
Licensing Agreements [Member]
Jun. 30, 2014
Licensing Agreements [Member]
Dec. 31, 2007
Licensing Agreements [Member]
Minimum [Member]
Dec. 31, 2007
Licensing Agreements [Member]
Maximum [Member]
Jun. 30, 2014
Lease Agreements [Member]
Dec. 31, 2013
Lease Agreements [Member]
Dec. 31, 2012
Lease Agreements [Member]
Jun. 30, 2014
Legal [Member]
Operating Leased Assets [Line Items]                        
Questionable expense       $ 1,500,000                
Number of licensed products       2                
Common stock shares exchange             15 years 20 years        
Royalties description                 67,800 64,600 13,300  
Questionable expense                       1,500,000
Common stock shares exchange                       868,213
Royalties description License fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed products it is currently developing.                      
Issuance of common stock to acquire Medeor, License agreement   $ 3,750,000                      
Royalty payments description    
(A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product.
                  
Royalty received by licensee description    
 (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.